The efficacy of booster doses was illustrated in a study of 182, 122 people in Israel who were ≥ 60 years and who received a second booster dose (4th overall dose) and were matched to compare to people who received only the first booster dose (3rd overall dose) of BNT162b2 demonstrated excellent efficacy of the vaccine for preventing symptomatic disease, hospitalization, and death.